High doses of 5-fluorouracil and epirubicin with or without cisplatin in advanced gastric cancer: A randomized study

被引:23
作者
Roth, A
Kolaric, K
Zupanc, D
Oresic, V
Roth, A
Ebling, Z
机构
[1] Univ Zagreb, Univ Hosp Tumors, HR-10002 Zagreb, Croatia
[2] Hlth Ctr Osijek, Dept Family Med, Osijek, Croatia
关键词
cisplatin; epirubicin; 5-fluorouracil; gastric cancer;
D O I
10.1177/030089169908500404
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: A prospective randomized clinical study was performed in patients with locally advanced or metastatic gastric cancer. The purpose of the study was to determine the activity of high doses of 5-fluorouracil and epirubicin (FE) vs the same combination + cisplatin (FEP), and particularly the value of cisplatin in the combination. Patients and methods: A total of 122 patients was included in the study; 110 of them were assessable. In the FE arm, the treatment involved 1000 mg/m(2) in a 6-hr infusion of 5-fluorouracil on days 1, 2, 3, 4 and 5 and 120 mg/m(2) of epirubicin iv on day 1. In the FEP arm, the same combination of cytostatics + cisplatin (30 mg/m(2)) was administered on days 2 and 4. The cycles were repeated after 4 weeks. Altogether, 468 cycles of chemotherapy were given (FE, 240; FEP, 228). Results: In the FE arm, 56 patients were assessable, with 2 complete and 14 partial remissions (28.6%); in the FEP arm, 4 complete and 19 partial remissions (42.6%) were observed in 54 assessable patients. Median survival in the FE group was 7.1 months and in the FEP group 9.6 months. The survival difference was statistically significant (Cox's test, P <0.05). The most frequent side effects included grade 2 and 3 alopecia (FE, 93%; FEP, 94%) and grade 2 and 3 vomiting (FE, 20%; FEP, 35%). Grade 3 and 4 leukopenia was observed in 9% of patients in the FE group and in 13% of patients in the FEP group, with 6 cases of febrile neutropenia (FE, 4%; FEP, 7%). Stenocardia was registered in 1 patient in the FE group and in 2 patients in the FEP group. No treatment-related death was registered. Conclusions: The addition of cisplatin to high doses of 5-fluorouracil and epirubicin resulted in a statistically significant better survival of treated patients.
引用
收藏
页码:234 / 238
页数:5
相关论文
共 25 条
[1]  
Alexander H. Richard, 1997, P1021
[2]  
[Anonymous], P AM SOC CLIN ONCOL
[3]  
COCCONI G, 1982, CANCER TREAT REP, V66, P1263
[4]   A PHASE-II STUDY IN ADVANCED GASTROESOPHAGEAL CANCER USING EPIRUBICIN AND CISPLATIN IN COMBINATION WITH CONTINUOUS-INFUSION 5-FLUOROURACIL (ECF) [J].
FINDLAY, M ;
CUNNINGHAM, D ;
NORMAN, A ;
MANSI, J ;
NICOLSON, M ;
HICKISH, T ;
NICOLSON, V ;
NASH, A ;
SACKS, N ;
FORD, H ;
CARTER, R ;
HILL, A .
ANNALS OF ONCOLOGY, 1994, 5 (07) :609-616
[5]  
FRAILE RJ, 1980, CANCER RES, V40, P2223
[6]  
*GASTR TUM STUD GR, 1979, CANC TREAT REP, V63, P1871
[7]   Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer [J].
Glimelius, B ;
Ekstrom, K ;
Hoffman, K ;
Graf, W ;
Sjoden, PO ;
Haglund, U ;
Svensson, C ;
Enander, LK ;
Linne, T ;
Sellstrom, H ;
Heuman, R .
ANNALS OF ONCOLOGY, 1997, 8 (02) :163-168
[8]  
KLEIN H O, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P84
[9]  
KOLARIC K, 1990, ANN ONCOL S, V1, P63
[10]  
LOKICH J, 1981, CANCER, V48, P2565, DOI 10.1002/1097-0142(19811215)48:12<2565::AID-CNCR2820481204>3.0.CO